Trial Profile
A Single Arm, Open-label, Multicenter Study Evaluating the Long-term Safety and Tolerability of 0.5 mg Fingolimod (FTY720) Administered Orally Once Daily in Patients With Relapsing Forms of Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational
- Acronyms LONGTERMS
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record. (19 Oct 2018)
- 02 Feb 2019 The trial has been completed in United Kingdom according to the European Clinical Trials Database record.
- 05 Dec 2018 Status changed from active, no longer recruiting to completed.